Modifiserte bioaktive fettsyrer - ny kreftbehandling?
- Prosjektnummer
- 911037
- Ansvarlig person
- Rolf K. Berge
- Institusjon
- Universitetet i Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Forskningsaktivitet
Immunomodulating effects of 3-thia fatty acids in activated peripheral blood mononuclear cells. Eur J Clin Invest 33, 426-433.
2003
Disturbed glutathione metabolism and decreased antioxidant levels in human immunodeficiency virus-infected patients during highl
2003
Impact of mitochondrial beta-oxidation in fatty acid-mediated inhibition of glioma cell proliferation. J Lipid Res 44, 118-127.
2003
Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 38, 543-548.
2003
Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochem
2003
Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia. Am J Clin Nutr 78, 117-
2003
Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differe
2003
Arachidonic acid-dependent inhibition of adipocyte differentiation requires PKA activity and is associated with sustained expres
2003
Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leu
2003
Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opin Ther Targets 7, 663-677.
2003
Cataract formation in Atlantic salmon, Salmo salar L., smolt relative to dietary pro- and antioxidants and lipid level. J Fish D
2003
Effects of the modified fatty acid and TTA on cell profileration and induction of cell death. Dr. philos,
- Disputert:
- april 2003
- Hovedveileder:
Clinical and operational challenges in the control of tuberculosis in south Ethiopia
- Disputert:
- juni 2003
- Hovedveileder:
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest